Quotient Limited Revenue Growth Rates (QTNT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Quotient Limited  (NASDAQ: QTNT)
 

QTNT's Revenue Growth by Quarter and Year

Quotient Limited's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

QTNT Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter March -
3rd Quarter December 9.05
2nd Quarter September 8.74
1st Quarter June 8.69
FY 26.48

QTNTs Annual Revenue
Quotient Limited's Revenue in the fiscal year 2022 $ 37.94 millions
Quotient Limited's Revenue in the fiscal year 2021 $ 43.38 millions
Quotient Limited's Revenue in the fiscal year 2020 $ 32.66 millions
Quotient Limited's Revenue in the fiscal year 2019 $ 29.13 millions
Quotient Limited's Revenue in the fiscal year 2018 $ 24.73 millions




QTNT Revenue third quarter 2023 Y/Y Growth Comment
Quotient Limited reported fall in Revenue in the third quarter 2023 by -11.01% to $ 9.05 millions, from the same quarter in 2022.
The decline in the third quarter 2023 Quotient Limited's Revenue compares unfavorably to the Company's average Revenue increase of 12.42%.

Looking into third quarter 2023 results within In Vitro & In Vivo Diagnostic Substances industry 12 other companies have achieved higher Revenue growth. While Quotient Limited' s Revenue decrease of -11.01% ranks overall at the positon no. 3078 in the third quarter 2023.


QTNT Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter March - 1.56 % 10.8 % 5.07 %
3rd Quarter December -11.01 % 16.23 % 10.2 % 18.15 %
2nd Quarter September -7.71 % -41.07 % 104.71 % 25.6 %
1st Quarter June -4.4 % 1.91 % 9.18 % 3.68 %
FY   - -11.2 % 32.82 % -

Financial Statements
Quotient Limited's third quarter 2023 Revenue $ 9.05 millions QTNT's Income Statement
Quotient Limited's third quarter 2022 Revenue $ 10.17 millions Quarterly QTNT's Income Statement


QTNT Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter March - -3.74 % 10.17 % 9.57 %
3rd Quarter December 3.55 % 7.39 % -45.55 % 1.15 %
2nd Quarter September 0.58 % 4.18 % 80.16 % -3.92 %
1st Quarter June -11.24 % -5.71 % 2.53 % -1.33 %
FY (Year on Year)   - -11.2 % 32.82 % -


Back to QTNT Growth rate Comparisons >> Back to QTNT Growth rate Comparisons >>


Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #13
Healthcare Sector #456
Overall #3078

Revenue Y/Y Growth Statistics
High Average Low
104.77 % 12.42 % -41.07 %
(Sep 30 2020)   (Sep 30 2021)
Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #13
Healthcare Sector #456
Overall #3078
Revenue Y/Y Growth Statistics
High Average Low
104.77 % 12.42 % -41.07 %
(Sep 30 2020)   (Sep 30 2021)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Quotient Limited's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
80.03 % 2.99 % -45.53 %
(Sep 30 2020)  


QTNT's III. Quarter Q/Q Revenue Comment
Quotient Limited achieved in the III. Quarter 2023 above company average sequential Revenue growth of 3.55%, to $ 9.05 millions, from $8.74 millions in the second quarter.

Within In Vitro & In Vivo Diagnostic Substances industry 8 other companies have achieved higher Revenue quarter on quarter growth. While Quotient Limited's Revenue growth quarter on quarter, overall rank is 1460.


Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #9
Healthcare Sector #226
Overall #1460
Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #9
Healthcare Sector #226
Overall #1460
Revenue Q/Q Growth Statistics
High Average Low
80.03 % 2.99 % -45.53 %
(Sep 30 2020)  


QTNT's III. Quarter Q/Q Revenue Comment
Quotient Limited achieved in the III. Quarter 2023 above company average sequential Revenue growth of 3.55%, to $ 9.05 millions, from $8.74 millions in the second quarter.

Within In Vitro & In Vivo Diagnostic Substances industry 8 other companies have achieved higher Revenue quarter on quarter growth. While Quotient Limited's Revenue growth quarter on quarter, overall rank is 1460.


Quotient Limited's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)		 12 Months Ending
(Dec 31 2021)
Cumulative Revenue 12 Months Ending $ 36.27 $ 37.39 $ 38.12 $ 38.51 $ 38.37
Y / Y Revenue Growth (TTM) -5.47 % 1.21 % -12.46 % -11.22 % -9.6 %
Year on Year Revenue Growth Overall Ranking # 3295 # 0 # 2868 # 3133 # 3063
Seqeuential Revenue Change (TTM) -3 % -1.91 % -1.03 % 0.39 % 3.85 %
Seq. Revenue Growth (TTM) Overall Ranking # 3364 # 0 # 3253 # 1123 # 3639


Cumulative Revenue growth Comment
For the 12 months ended Dec 31 2022 Quotient Limited reported a decrease in Revenue by -5.47% year on year, to $36 millions, compare to the 1.21% growth at Sep 30 2022.

In the Healthcare sector 444 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3295.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 11
Healthcare Sector # 445
Overall # 3295

Revenue TTM Y/Y Growth Statistics
High Average Low
34.21 %
 11.73 %
-30.22 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 11
Sector # 455
S&P 500 # 3364
Cumulative Revenue growth Comment
For the 12 months ended Dec 31 2022 Quotient Limited reported a decrease in Revenue by -5.47% year on year, to $36 millions, compare to the 1.21% growth at Sep 30 2022.

In the Healthcare sector 444 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3295.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 11
Healthcare Sector # 445
Overall # 3295

Revenue TTM Y/Y Growth Statistics
High Average Low
34.21 %
11.73 %
-30.22 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 11
Sector # 455
S&P 500 # 3364




Other Revenue Growth
In Vitro & In Vivo Diagnostic Substances Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
QTNT's Revenue Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decrease for the quarter ending Dec 31 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2022
Amgen Inc -0.10%$ -0.102 millions
Bausch Health Companies Inc -0.14%$ -0.137 millions
Bio rad Laboratories Inc -0.34%$ -0.339 millions
Nrc Health-0.40%$ -0.402 millions
Asensus Surgical Inc -0.48%$ -0.485 millions
Bausch and Lomb Corp-0.50%$ -0.500 millions
Teleflex Incorporated-0.51%$ -0.514 millions
Elite Pharmaceuticals Inc -0.62%$ -0.619 millions
Meihua International Medical Technologies Co Ltd-0.66%$ -0.665 millions
Ambrx Biopharma Inc -0.71%$ -0.711 millions
Chemed Corporation-0.85%$ -0.851 millions
Vycor Medical Inc -0.90%$ -0.899 millions
Fonar Corporation-0.91%$ -0.911 millions
Davita Inc -0.92%$ -0.920 millions
Syneos Health Inc -0.98%$ -0.984 millions
Reshape Lifesciences Inc-1.02%$ -1.018 millions
Accuray Incorporated-1.30%$ -1.303 millions
Bellicum Pharmaceuticals Inc -1.57%$ -1.575 millions
Pliant Therapeutics Inc -1.70%$ -1.701 millions
Royalty Pharma Plc-1.73%$ -1.729 millions
Precipio inc -1.81%$ -1.807 millions
Integra Lifesciences Holdings Corp-1.85%$ -1.850 millions
Nexgel Inc -1.88%$ -1.876 millions
Novartis Ag-1.98%$ -1.984 millions
Theravance Biopharma inc -1.99%$ -1.987 millions
Orthofix Medical Inc -2.27%$ -2.267 millions
Travere Therapeutics Inc -2.41%$ -2.412 millions
Heska Corporation-2.54%$ -2.542 millions
Sangamo Therapeutics Inc -2.70%$ -2.701 millions
Glaukos Corp-2.75%$ -2.748 millions


About Quotient Limited Revenue Growth Rates (QTNT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Quotient Ltd (CIK 1596946).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000950170-23-002382
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Quotient Ltd’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.